CMPX: Compass Therapeutics Corp Cash Calculated per Single Share

Compass Therapeutics Corp - graphic logo of issuer CMPX

Compass Therapeutics develops bispecific antibodies to combat solid tumors by combining the blockade of cancer growth with an immune response. The cash per share trend visualizes the actual volume of liquidity, where 0.91 shows the level of this metric. The scientific team is effectively advancing the therapy portfolio, while management is currently prioritizing the most successful clinical programs following an analysis of interim data.

Compass Therapeutics (CMPX) - Cash per Share from 07/04/2022 to 11/20/2026

Comprehensive metric breakdowns and analytics for compasstherapeutics.com (CMPX)

- current quotes and average value forecast:
- cash availability and cash flow indicators:
Comprehensive company analysis:Compass Therapeutics (CMPX)
Flagship merchandise of Compass Therapeutics

For Compass Therapeutics (CMPX), whose development depends on clinical trials and patent protection, the cash per share metric on GURU.Markets reflects the company's ability to fund R&D independently of macro cycles. This metric is calculated by dividing net liquidity by the number of shares outstanding, allowing investors to assess the business's margin of safety and the risk of equity dilution when seeking new financing.